Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5203_Библиотеки_им_академика_М_И_Перельмана.pdf
300
270. Dutta P, Das S, Fershko A. Non-aromatic anticonvulsant (divalproex sodium)-induced
drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Cureus.
2021;13(9):e17860.
271. Sturla Álvarez DA, Sánchez Marcos E, de Lucas Collantes C, et al. Fanconi syndrome
secondary to sodium valproate therapy: experience and literature review. Pediatr Neurol.
2022;130:53–9.
272. Goodman LS, Swinyard EA, Toman JE.Studies on the anticonvulsant properties of diphenylhydantoin. Fed Proc. 1946;5(1 Pt 2):180.
273. Bashinski B. Treatment of epilepsy in children with sodium dilantin. J Med Assoc Ga.
1946;35:228.
274. Mc GJ, Martin RE. Dilantin intoxication. Clin Proc Child Hosp Dist Columbia.
1949;5(11):316–9.
275. Sweet RD.A xed skin eruption due to phenytoin sodium. Lancet. 1950;1(6594):68.
276. Pfeie CE, Adler DS, Gannaway WL.Phenytoin sodium solubility in three intravenous solutions. Am J Hosp Pharm. 1981;38(3):358–62.
277. Kang Y, Yang R, Wei Z, etal. Phenytoin sodium-ameliorated gingival broblast aging is
associated with autophagy. J Periodontal Res. 2020;55(5):642–50.
278. Kathiravan M, Kavitha S, Shanthi R.To determine the effect of long-term antiepileptic drug
on the serum folate and vitamin B12 among epileptic patients. Sci Rep. 2021;11(1):4393.
279. Sangeetha A, Bobby Z, Wadwekar V, etal. Atherogenic risk factors among young Indian
adults with epilepsy on treatment with phenytoin: need for novel therapeutic strategies.
Neurol India. 2021;69(4):957–61.
280. Morán-Mariños C, Alva-Diaz C, De la Cruz Ramirez W, etal. Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by phenytoin re-exposure: case report and
systematic review. Acta Clin Belg. 2022;77(1):177–85.
281. Urushidani S. A phenytoin-induced ataxia mimicking a stroke. Am J Emerg Med.
2022;60:226.e5–6.
282. Asadi-Pooya AA, Rostaminejad M, Zeraatpisheh Z, etal. Cosmetic adverse effects of antiseizure medications; A systematic review. Seizure. 2021;91:9–21.
283. Minowa E, Hayashi Y, Goh K, etal. Enhancement of receptor-mediated calcium responses
by phenytoin through the suppression of calcium excretion in human gingival broblasts. J
Periodontal Res. 2023;58(2):274–82.
284. Klowak JA, Hewitt M, Catenacci V, etal. Levetiracetam versus phenytoin or fosphenytoin for
second-line treatment of pediatric status epilepticus: a meta-analysis. Pediatr Crit Care Med.
2021;22(9):e480–e91.
285. Mastroianni G, Iannone LF, Roberti R, etal. Management of status epilepticus in patients
with liver or kidney disease: a narrative review. Expert Rev Neurother. 2021;21(11):1251–64.
286. Mohammadi M, Kadivar M, Sangsari R, etal. Comparing the efcacy and safety of levetiracetam versus phenytoin for treating the acute phase of neonatal seizures. Iran J Child
Neurol. 2023;17(1):65–71.
287. Alix V, James M, Jackson AH, etal. Efcacy of fosphenytoin as rst-line antiseizure medication for neonatal seizures compared to phenobarbital. J Child Neurol. 2021;36(1):30–7.
288. Shi R, Yin HQ, Wang ZZ. [Efcacy and safety of levetiracetam versus phenytoin as secondline drugs for the treatment of children with convulsive status epilepticus: a meta analysis].
Zhongguo Dang Dai Er Ke Za Zhi. 2021;23(4):356–62.
289. Guidotti I, Lugli L, Ori L, etal. Neonatal seizures treatment based on conventional multichannel EEG monitoring: an overview of therapeutic options. Expert Rev Neurother.
2022;22(7):623–38.
290. Dell’Aquila J, Soti V.Treating status epilepticus: phenytoin versus levetiracetam. Cureus.
2021;13(10):e18515.
291. Huo X, Xu X, Li M, etal. Effectiveness of antiseizure medications therapy in preventing seizures in brain injury patients: a network meta-analysis. Front Pharmacol. 2022;13:1001363.
W. Jing et al.
2 Antiseizure Medications
292. Panda PK, Panda P, Dawman L, etal. Efcacy of lacosamide and phenytoin in status epilepticus: a systematic review. Acta Neurol Scand. 2021;144(4):366–74.
293. Ferner R, Day R, Bradberry SM.Phenytoin and damage to the cerebellum– a systematic
review of published cases. Expert Opin Drug Saf. 2022;21(7):957–77.
294. Purkins L, Wood N, Ghahramani P, etal. Coadministration of voriconazole and phenytoin:
pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol. 2003;56(Suppl
1):37–44.
295. Muñoz-Vendrell A, Teixidor S, Sala-Padró J, etal. Intravenous lacosamide and phenytoin for
the treatment of acute exacerbations of trigeminal neuralgia: a retrospective analysis of 144
cases. Cephalalgia. 2022;42(10):1031–8.
296. Degen R, Lässker G, Edelmann R. [Long term therapy with nitrazepam in children
with infantile spasms and myoclonic-astatic ts]. Psychiatr Neurol Med Psychol Beih.
1975;20–21:90–3.
297. Kangas L, Kanto J, Syvälahti E.Plasma nitrazepam concentrations after an acute intake and
their correlation to sedation and serum growth hormone levels. Acta Pharmacol Toxicol.
1977;41(1):65–73.
298. Khorana AB. Nitrazepam in emotional disorders of childhood. Indian J Psychiatry.
1981;23(1):79–81.
299. Ebata T, Izumi H, Aizawa H, etal. Effects of nitrazepam on nocturnal scratching in adults
with atopic dermatitis: a double-blind placebo-controlled crossover study. Br J Dermatol.
1998;138(4):631–4.
300. Zahan S, Sahu JK, Madaan P, etal. Effectiveness and safety of nitrazepam in children with
resistant West syndrome. Indian J Pediatr. 2022;89(1):37–44.
301. Zhongshu Z, Weiming Y, Yukio F, etal. Clinical analysis of West syndrome associated with
phenylketonuria. Brain Dev. 2001;23(7):552–7.
302. Kaushik JS, Patra B, Sharma S, etal. Clinical spectrum and treatment outcome of West syndrome in children from northern India. Seizure. 2013;22(8):617–21.
303. Beran RG.Use of interval therapy with benzodiazepines to prevent seizure recurrence in
stressful situations. Brain Sci. 2022;12(5):512.
304. Iyer A, Appleton R. Improving outcomes in infantile spasms: role of pharmacotherapy.
Paediatr Drugs. 2016;18(5):357–66.
305. Hosain SA, Green NS, Solomon GE, etal. Nitrazepam for the treatment of Lennox-Gastaut
syndrome. Pediatr Neurol. 2003;28(1):16–9.
306. Kagitani-Shimono K, Imai K, Otani K, etal. Epilepsy in Wolf-Hirschhorn syndrome (4p-).
Epilepsia. 2005;46(1):150–5.
307. Shields MD, Hicks EM, Macgregor DF, etal. Infantile spasms associated with theophylline
toxicity. Acta Paediatr. 1995;84(2):215–7.
308. Dreifuss F, Farwell J, Holmes G, etal. Infantile spasms. Comparative trial of nitrazepam and
corticotropin. Arch Neurol. 1986;43(11):1107–10.
309. Song JM, Hahn J, Kim SH, etal. Efcacy of treatments for infantile spasms: a systematic
review. Clin Neuropharmacol. 2017;40(2):63–84.
310. Saarelainen L, Taipale H, Koponen M, etal. The incidence of benzodiazepine and related drug
use in persons with and without Alzheimer’s disease. J Alzheimers Dis. 2016;49(3):809–18.
311. Jan JE, Riegl JA, Crichton JU, etal. Nitrazepam in the treatmet of epilepsy in childhood. Can
Med Assoc J. 1971;104(7):571–5.
312. Kagota S, Morikawa K, Ishida H, et al. Vasorelaxant effects of benzodiazepines, nonbenzodiazepine sedative-hypnotics, and tandospirone on isolated rat arteries. Eur J Pharmacol.
2021;892:173744.
313. Iqbal U, Nguyen PA, Syed-Abdul S, etal. Is long-term use of benzodiazepine a risk for cancer? Medicine. 2015;94(6):e483.
314. Dennis J, Hunt A.Prolonged use of nitrazepam for epilepsy in children with tuberous sclerosis. Br Med J (Clin Res Ed). 1985;291(6497):692–3.
301
302
315. Lim HC, Nigro MA, Beierwaltes P, et al. Nitrazepam-induced cricopharyngeal dysphagia,
abnormal esophageal peristalsis and associated bronchospasm: probable cause of nitrazepamrelated sudden death. Brain Dev. 1992;14(5):309–14.
316. Zhao DY, Feng GJ, Wu XR, etal. Seizures induced by intraventricular microinjection of ionized cobalt in the rat--a new experimental model of epilepsy. Brain Res. 1985;342(2):323–9.
317. Liao CY, Chung CH, Lu KC, etal. Taking sleeping pills and the risk of chronic kidney disease:
a nationwide population-based retrospective cohort study. Front Pharmacol. 2020;11:524113.
318. Kassie GM, Roughead EE, Nguyen TA, etal. The risk of preoperative central nervous systemacting medications on delirium following hip or knee surgery: a matched case-control study.
Drug Saf. 2022;45(1):75–82.
319. Marson A, Burnside G, Appleton R, etal. The SANAD II study of the effectiveness and
cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal
epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Lancet. 2021;397(10282):1363–74.
320. Shi X, Wang Y, Zhang Y, etal. Effects of antiepileptic drugs polytherapy on pregnancy outcomes in women with epilepsy: an observation study in northwest China. Epilepsy Behav.
2022;135:108904.
321. Cohen JM, Alvestad S, Cesta CE, etal. Comparative safety of antiseizure medication monotherapy for major malformations. Ann Neurol. 2023;93(3):551–62.
322. Pekoz MT, Aslan-Kara K, Tekin B, etal. Birth outcomes in pregnant women with epilepsy: a
nationwide multicenter study from Türkiye. Epilepsia. 2023;64(9):2310–21.
323. Barry JM, French JA, Pennell PB, etal. Empiric dosing strategies to predict lamotrigine concentrations during pregnancy. Pharmacotherapy. 2023;43(10):998–1006.
324. Freund B, Chen B, Kaplan PW, etal. Managing antiseizure medications in pregnancy: is
earlier and more frequent monitoring better? Neurol Clin Pract. 2023;13(4):e200169.
325. Kacirova I, Grundmann M, Brozmanova H. Monitoring of lamotrigine concentrations in
mothers, colostrum, and breastfed newborns during the early postpartum period. Biomed
Pharmacother. 2022;151:113167.
326. Pedersen S, Kverneland M, Rudi K, etal. Decreased serum concentrations of antiseizure
medications in children with drug resistant epilepsy following treatment with ketogenic diet.
Epilepsia Open. 2023;8(3):858–66.
327. Shi XY, Ju J, Lu Q, et al. Both epilepsy and anti-seizure medications affect bone metabolism in children with self-limited epilepsy with centrotemporal spikes. Epilepsia.
2023;64(10):2667–78.
328. Assis T, Bacellar A, Côrtes L, etal. Trends in prescribing patterns of antiepileptic drugs among
older adult inpatients in a Brazilian tertiary center. Arq Neuropsiquiatr. 2021;79(1):22–9.
329. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison
between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy.
The UK Lamotrigine Elderly Study Group. Epilepsy Res. 1999;37(1):81–7.
330. Daneshyar S, Ghiasian M, Moradi S, etal. Efcacy of levetiracetam, lamotrigine and sodium
valproate on seizure attacks and EEG disorders in patients with juvenile myoclonic epilepsy:
a double blind randomized clinical trial. Caspian J Intern Med. 2022;13(3):617–22.
331. Larsson D, Baftiu A, Johannessen Landmark C, et al. Association between antiseizure
drug monotherapy and mortality for patients with poststroke epilepsy. JAMA Neurol.
2022;79(2):169–75.
332. Loikas D, Linnér L, Sundström A, etal. Post-stroke epilepsy and antiepileptic drug use in
men and women. Basic Clin Pharmacol Toxicol. 2021;129(2):148–57.
333. van Opijnen MP, van der Meer PB, Dirven L, etal. The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide. J Neurooncol. 2021;154(1):73–81.
334. Mahamud Z, Håkansson S, Burman J, etal. Retention of antiseizure medications for epilepsy in multiple sclerosis: a retrospective observational study. Epilepsy Behav. 2021;121(Pt
A):108034.
W. Jing et al.
2 Antiseizure Medications
335. Le Roux M, Barth M, Gueden S, etal. CACNA1A-associated epilepsy: electroclinical ndings and treatment response on seizures in 18 patients. Eur J Paediatr Neurol. 2021;33:75–85.
336. Milano C, Turco F, Pizzanelli C, etal. Response to levetiracetam or lamotrigine in subjects
with Juvenile Myoclonic Epilepsy previously treated with valproic acid: a single center retrospective study. Epilepsy Behav. 2021;115:107706.
337. Zhang N, Yang D, Niu C, etal. Comparison of the retention rate, safety, and efcacy of two
different titration protocols for lamotrigine in newly diagnosed epilepsy patients. Expert Rev
Neurother. 2022;22(11–12):1025–9.
338. Chung SJ, Ahn KM, Oh JH, etal. Incidence rates of severe cutaneous adverse reactions due
to antiseizure medication: a nationwide study using health claims data in Korea. Epilepsia.
2021;62(1):250–7.
339. Fukasawa T, Takahashi H, Takahashi K, etal. Risk of Stevens-Johnson syndrome and toxic
epidermal necrolysis associated with anticonvulsants in a Japanese population: matched casecontrol and cohort studies. Allergol Int. 2021;70(3):335–42.
340. Shi YW, Wang J, Min FL, etal. HLA risk alleles in aromatic antiepileptic drug-induced
maculopapular exanthema. Front Pharmacol. 2021;12:671572.
341. Edinoff AN, Nguyen LH, Fitz-Gerald MJ, etal. Lamotrigine and Stevens-Johnson syndrome
prevention. Psychopharmacol Bull. 2021;51(2):96–114.
342. Mortazavi H, Rostami A, Firooz A, etal. Association between human leukocyte antigens and
cutaneous adverse drug reactions to antiepileptics and antibiotics in the Iranian population.
Dermatol Ther. 2022;35(5):e15393.
343. Packard E, Kalayanamitra R, Shahid Z, etal. DRESS is a mess: a case of cross reactivity
between lacosamide and lamotrigine. S D Med. 2021;74(7):324–8.
344. Shirzadi M, Saunes M, Reimers A, etal. Rash during lamotrigine treatment is not always
drug hypersensitivity: a retrospective cohort study among children and adults. Seizure.
2021;89:12–8.
345. Alfares I, Javaid MS, Chen Z, etal. Sex differences in the risk of cutaneous adverse drug
reactions induced by antiseizure medications: a systematic review and meta-analysis. CNS
Drugs. 2021;35(2):161–76.
346. Zhu X, Xiao T, Huang S, etal. Case report: predicting the range of lamotrigine concentration
using pharmacokinetic models based on Monte Carlo simulation: a case study of antiepileptic
drug-related leukopenia. Front Pharmacol. 2021;12:706329.
347. Wang C, Fan Z, He Y, et al. Analysis of the clinical characteristics of lamotrigine-induced
haemophagocytic lymphohistiocytosis. J Clin Pharm Ther. 2022;47(6):745–51.
348. Wang W, Battini V, Carnovale C, et al. A novel approach for pharmacological substantiation of safety signals using plasma concentrations of medication and administrative/healthcare databases: a case study using Danish registries for an FDA warning on lamotrigine.
Pharmacol Res. 2023;193:106811.
349. Christensen J, Trabjerg BB, Dreier JW.Cardiac morbidity and mortality associated with the
use of lamotrigine. Epilepsia. 2022;63(9):2371–80.
350. Auerbach DS, Muniz CF.Cardiac safety of lamotrigine: still awaiting a verdict. Neurology.
2022;98(17):697–8.
351. Restrepo JA, MacLean R, Celano CM, etal. The assessment of cardiac risk in patients taking
lamotrigine; a systematic review. Gen Hosp Psychiatry. 2022;78:14–27.
352. Aboukaoud M, Wilf-Yarkoni A, Maor E. Investigation of cardiac arrhythmia events in
patients treated with lamotrigine: FDA adverse event reporing system analysis. Epilepsia.
2023;64(9):2322–9.
353. Bunschoten JW, Husein N, Devinsky O, etal. Sudden death and cardiac arrhythmia with
lamotrigine: a rapid systematic review. Neurology. 2022;98(17):e1748–e60.
354. Nightscales R, Barnard S, Laze J, etal. Risk of sudden unexpected death in epilepsy (SUDEP)
with lamotrigine and other sodium channel-modulating antiseizure medications. Epilepsia
Open. 2023;8(2):334–45.
303
304
355. Hu W, Chen L, Li H, et al. Eye disorders associated with newer antiepileptic drugs: a
real-world disproportionality analysis of FDA adverse event reporting system. Seizure.
2022;96:66–73.
356. Chen Y, Chen J, Zhuang X, etal. Risk factors of elevated blood ammonia level in epilepsy
patients treated with lamotrigine. Medicine (Baltimore). 2022;101(26):e29780.
357. Tran DH, Jaggon KS, Mikdashi J, etal. Lamotrigine-induced lupus with aseptic meningitis
and hemophagocytic lymphohistiocytosis. Cureus. 2022;14(9):e29629.
358. Watzal V, Godbersen GM, Weidenauer A, etal. Case report: interstitial pneumonitis after
initiation of lamotrigine. Front Psych. 2023;14:1203497.
359. Ge J, Cao SS, Cao XY, et al. Lamotrigine induced priapism in children: case analysis and
literature review. J Int Med Res. 2022;50(11):3000605221133988.
360. Huang J, Fan X, Jin X, etal. Dual-pocket inhibition of Na(v) channels by the antiepileptic
drug lamotrigine. Proc Natl Acad Sci USA. 2023;120(41):e2309773120.
361. Chmielewska N, Wawer A, Wicik Z, etal. miR-9a-5p expression is decreased in the hippocampus of rats resistant to lamotrigine: a behavioural, molecular and bioinformatics assessment. Neuropharmacology. 2023;227:109425.
362. Faustmann TJ, Corvace F, Faustmann PM, et al. Effects of lamotrigine and topiramate
on glial properties in an astrocyte-microglia co-culture model of inammation. Int J
Neuropsychopharmacol. 2022;25(3):185–96.
363. Filiz AK, Gumus E, Karabulut S, etal. Protective effects of lamotrigine and vitamin B12 on pentylenetetrazole-induced epileptogenesis in rats. Epilepsy Behav.
2021;118:107915.
364. Zubareva OE, Sinyak DS, Kalita AD, etal. Antiepileptogenic effects of anakinra, lamotrigine
and their combination in a lithium-pilocarpine model of temporal lobe epilepsy in rats. Int J
Mol Sci. 2023;24(20):15400.
365. Łuszczki JJ, Podgórska D, Kozińska J, etal. Polygonogram with isobolographic synergy for
three-drug combinations of phenobarbital with second-generation antiepileptic drugs in the
tonic-clonic seizure model in mice. Pharmacol Rep. 2021;73(1):111–21.
366. Onishi K, Kamida T, Fujiki M, etal. Anticonvulsant and antioxidant effects of lamotrigine on
pilocarpine-induced status epilepticus in mice. Neuroreport. 2023;34(1):61–6.
367. Abdelmonem R, El-Enin HAA, Abdelkader G, et al. Formulation and characterization
of lamotrigine nasal insert targeted brain for enhanced epilepsy treatment. Drug Deliv.
2023;30(1):2163321.
368. Mohsen AM, Salama AAA, Asfour MH.Cubosome-based thermosensitive in situ gelling
system for intranasal administration of lamotrigine with enhanced antiepileptic efcacy.
Pharm Dev Technol. 2023;28(6):520–34.
369. Jeong JH, Bahk WM, Woo YS, etal. Korean medication algorithm project for bipolar disorder 2022: comparisons with other treatment guidelines. Clin Psychopharmacol Neurosci.
2023;21(1):32–48.
370. Vieta E, Ghorpade S, Biswas A, etal. Lamotrigine efcacy, safety, and tolerability for women
of childbearing age with bipolar I disorder: meta-analysis from four randomized, placebocontrolled maintenance studies. Eur Neuropsychopharmacol. 2024;78:81–92.
371. Thompson SI, El-Saden SM.Lamotrigine for treating anger in veterans with posttraumatic
stress disorder. Clin Neuropharmacol. 2021;44(5):184–5.
372. Cuomo A, Amore M, Vampini C, etal. [Lamotrigine in bipolar disorder: preventing depression to treat the disease]. Riv Psichiatr. 2021;56(1):1–11.
373. Celdran de Castro A, Nascimento FA, Beltran-Corbellini Á, et al. Levetiracetam, from
broad-spectrum use to precision prescription: a narrative review and expert opinion. Seizure.
2023;107:121–31.
374. Kharel S, Ojha R, Khanal S. Levetiracetam versus oxcarbazepine as monotherapy in
newly diagnosed focal epilepsy: a systematic review and meta-analysis. Brain Behav.
2022;12(11):e2779.
W. Jing et al.
2 Antiseizure Medications
375. Gerstl L, Willimsky E, Rémi C, etal. A systematic review of seizure-freedom rates in patients
with benign epilepsy of childhood with centrotemporal spikes receiving antiepileptic drugs.
Clin Neuropharmacol. 2021;44(2):39–46.
376. Abdelmesih SK, Elkhateeb N, Zakaria M, etal. Initial levetiracetam versus valproate monotherapy in antiseizure medicine (ASM)-naïve pediatric patients with idiopathic generalized
epilepsy with tonic-clonic seizures. Seizure. 2021;91:263–70.
377. Manreza MLG, Pan TA, Carbone EQ, etal. Efcacy and safety of levetiracetam as adjunctive
therapy for refractory focal epilepsy. Arq Neuropsiquiatr. 2021;79(4):290–8.
378. Ballvé A, Salas-Puig J, Quintana M, etal. Levetiracetam as rst-line monotherapy for idiopathic generalized epilepsy in women. Acta Neurol Scand. 2021;143(4):407–12.
379. van der Meer PB, Dirven L, van den Bent MJ, etal. Prescription preferences of antiepileptic
drugs in brain tumor patients: an international survey among EANO members. Neurooncol
Pract. 2022;9(2):105–13.
380. van der Meer PB, Maschio M, Dirven L, etal. First-line levetiracetam versus enzyme- inducing
antiseizure medication in glioma patients with epilepsy. Epilepsia. 2023;64(1):162–9.
381. Hedges A, Findlay MC, Davis GE, etal. Levetiracetam dosing for seizure prophylaxis in
neurocritical care patients. Brain Inj. 2023;37(10):1167–72.
382. Peter-Derex L, Philippeau F, Garnier P, etal. Safety and efcacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage
(PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol.
2022;21(9):781–91.
383. Döring JH, Saffari A, Bast T, etal. Efcacy, tolerability, and retention of antiseizure medications in PRRT2-associated infantile epilepsy. Neurol Genet. 2022;8(5):e200020.
384. Coppola A, Dubbioso R, Cuccurullo C, etal. Current treatment options for familial adult
myoclonus epilepsy. Epilepsia. 2023;64(Suppl 1):S58–63.
385. Zhang L, Li Y, Wang W, etal. Comparative antiseizure medications of adjunctive treatment
for children with drug-resistant focal-onset seizures: a systematic review and network metaanalysis. Front Pharmacol. 2022;13:978876.
386. Takebayashi Y, Neshige S, Shishido T, etal. Paradoxical effects of levetiracetam in people
with epilepsy with rhythmic epileptiform discharges. Epilepsy Behav. 2023;143:109225.
387. Horiguchi A, Koichihara R, Kikuchi K, etal. Efcacy of antiseizure medications in WolfHirschhorn syndrome. Neuropediatrics. 2023;54(5):339–43.
388. Wang QH, Cao JJ, Wang YY, etal. Efcacy of levetiracetam in STXBP1 encephalopathy with
different phenotypic and genetic spectra. Seizure. 2022;95:64–74.
389. Nagano M, Tagami T, Kaneko J, et al. Blood concentration of levetiracetam after bolus
administration in patients with status epilepticus. Seizure. 2021;89:41–4.
390. Yang L, Dong XZ, Cui XH, etal. Comparison of the efcacy and safety of levetiracetam and
phenytoin in the treatment of established status epilepticus: a systematic review and metaanalysis. J Clin Neurosci. 2021;89:422–9.
391. Angurana SK, Suthar R.Efcacy and safety of levetiracetam vs. phenytoin as second line
antiseizure medication for pediatric convulsive status epilepticus: a systematic review and
meta-analysis of randomized controlled trials. J Trop Pediatr. 2021;67(2):fmab014.
392. Haller JT, Bonnin S, Radosevich J.Rapid administration of undiluted intravenous levetiracetam. Epilepsia. 2021;62(8):1865–70.
393. Webb CA, Wanbon R, Otto ED.Levetiracetam for status epilepticus in adults: a systematic
review. Can J Hosp Pharm. 2022;75(1):46–53.
394. Köle MT, Sager SG, Zeynel H, etal. Efcacy of intravenous levetiracetam versus phenytoin
in convulsive status epilepticus and acute repetitive seizures in children. Childs Nerv Syst.
2022;38(7):1357–64.
395. Sharma SR, Sharma N, Hussain M, etal. Levetiracetam use during pregnancy in women with
active epilepsy: a hospital-based, retrospective study from a tertiary care hospital in North
Eastern INDIA.Neurol India. 2021;69(3):692–7.
305
306
396. Schelhaas M, Wegner I, Edens M, etal. Association of levetiracetam concentration with seizure frequency in pregnant women with epilepsy. Neurology. 2023;100(2):e172–e81.
397. Chen J, You X, Wu W, et al. Application of PBPK modeling in predicting maternal and fetal pharmacokinetics of levetiracetam during pregnancy. Eur J Pharm Sci.
2023;181:106349.
398. Susnerwala S, Joshi A, Deshmukh L, etal. Levetiracetam or phenobarbitone as a rst-line
anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized,
controlled, pragmatic trial. Hosp Pediatr. 2022;12(7):647–53.
399. Sortino V, Praticò A, Marino S, et al. Efcacy of the anti-seizure medications in acute
symptomatic neonatal seizures caused by stroke. A systematic review. Acta Biomed.
2022;93(6):e2022328.
400. Bromley RL, Bullen P, Campbell E, etal. Neurodevelopment of babies born to mothers with
epilepsy: a prospective observational cohort study. Epilepsia. 2023;64(9):2454–71.
401. Mari L, Placidi F, Romigi A, et al. Levetiracetam, lamotrigine and carbamazepine: which
monotherapy during pregnancy? Neurol Sci. 2022;43(3):1993–2001.
402. Verwoerd C, Limjoco J, Rajamanickam V, etal. Efcacy of levetiracetam and phenobarbital
as rst-line treatment for neonatal seizures. J Child Neurol. 2022;37(5):401–9.
403. Werhahn KJ, Trinka E, Dobesberger J, et al. A randomized, double-blind comparison
of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia.
2015;56(3):450–9.
404. Consoli D, Bosco D, Postorino P, et al. Levetiracetam versus carbamazepine in patients
with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC
Project). Cerebrovasc Dis. 2012;34(4):282–9.
405. Tekin U, Tekin E, Uçar HN.Irritability and its relationship with psychosocial symptoms and
quality of life in adolescents with epilepsy receiving levetiracetam therapy: a case-control
study. Epilepsy Behav. 2022;135:108877.
406. Dreier JW, Bjørk MH, Alvestad S, etal. Prenatal exposure to antiseizure medication and
incidence of childhood- and adolescence-onset psychiatric disorders. JAMA Neurol.
2023;80(6):568–77.
407. Onodera M, Saito T, Fukui A, etal. The high incidence and risk factors of levetiracetam and
lacosamide-related skin rashes in glioma patients. Clin Neurol Neurosurg. 2022;220:107366.
408. Gözükızıl ST, Aydın Z, Yalçın AD. Relationship between bone density and levetiracetam
monotherapy in epilepsy patients. Clin Neurol Neurosurg. 2022;218:107270.
409. Han Y, Yang J, Zhong R, etal. Side effects of long-term oral anti-seizure drugs on thyroid
hormones in patients with epilepsy: a systematic review and network meta-analysis. Neurol
Sci. 2022;43(9):5217–27.
410. Zhuo L, Zhang Y.Effects of new antiseizure medication on bone metabolism and bone mineral density in children: a meta-analysis. Front Pediatr. 2022;10:1015691.
411. Egunsola O, Choonara I, Sammons HM.Safety of levetiracetam in paediatrics: a systematic
review. PLoS One. 2016;11(3):e0149686.
412. Mahmoud A, Tabassum S, Al Enazi S, etal. Amelioration of levetiracetam-induced behavioral side effects by pyridoxine. A randomized double blind controlled study. Pediatr Neurol.
2021;119:15–21.
413. Giner-Soriano M, Marsal JR, Gomez-Lumbreras A, etal. Risk of ischaemic stroke associated
with antiepileptic drugs: a population-based case-control study in Catalonia. BMC Neurol.
2021;21(1):208.
414. Ip BY, Ko H, Wong GL, etal. Thromboembolic risks with concurrent direct oral anticoagulants
and antiseizure medications: a population-based analysis. CNS Drugs. 2022;36(12):1313–24.
415. Aydin H, Korkut O.Effect of levetiracetam therapy on electrocardiographic parameters. Arch
Pediatr. 2023;30(3):149–52.
416. Niidome K, Taniguchi R, Yamazaki T, etal. FosL1 is a novel target of levetiracetam for suppressing the microglial inammatory reaction. Int J Mol Sci. 2021;22(20):10962.
W. Jing et al.
2 Antiseizure Medications
417. Matsuo T, Komori R, Nakatani M, etal. Levetiracetam suppresses the inltration of neutrophils and monocytes and downregulates many inammatory cytokines during epileptogenesis in pilocarpine-induced status epilepticus mice. Int J Mol Sci. 2022;23(14):7671.
418. Mani V, Rashed Almutairi S.Impact of levetiracetam on cognitive impairment, neuroinammation, oxidative stress, and neuronal apoptosis caused by lipopolysaccharides in rats. Saudi
Pharm J. 2023;31(9):101728.
419. Yang L, Afroz S, Valsamis HA, et al. Early intervention with levetiracetam prevents the
development of cortical hyperexcitability and spontaneous epileptiform activity in two models of neurotrauma in rats. Exp Neurol. 2021;337:113571.
420. Vossel K, Ranasinghe KG, Beagle AJ, etal. Effect of levetiracetam on cognition in patients
with Alzheimer disease with and without epileptiform activity: a randomized clinical trial.
JAMA Neurol. 2021;78(11):1345–54.
421. Rao NR, Savas JN.Levetiracetam treatment normalizes levels of presynaptic endocytosis
machinery and restores nonamyloidogenic APP processing in app knock-in mice. J Proteome
Res. 2021;20(7):3580–9.
422. Alavi MS, Fanoudi S, Hosseini M, etal. Benecial effects of levetiracetam in streptozotocininduced rat model of Alzheimer’s disease. Metab Brain Dis. 2022;37(3):689–700.
423. Azeem GM, Faheem F, Farooq N, etal. Levetiracetam for the prophylaxis of migraine in
adults. Cureus. 2021;13(7):e16779.
424. Cavichioli AM, Santos-Silva T, Grace AA, etal. Levetiracetam attenuates adolescent stressinduced behavioral and electrophysiological changes associated with schizophrenia in adult
rats. Schizophr Bull. 2023;49(1):68–77.
425. Latini G, Verrotti A, Manco R, etal. Topiramate: its pharmacological properties and therapeutic efcacy in epilepsy. Mini Rev Med Chem. 2008;8(1):10–23.
426. Rheims S, Ryvlin P.Pharmacotherapy for tonic-clonic seizures. Expert Opin Pharmacother.
2014;15(10):1417–26.
427. Campos MSA, Ayres LR, Morelo MRS, etal. Comparative efcacy of antiepileptic drugs for
patients with generalized epileptic seizures: systematic review and network meta-analyses.
Int J Clin Pharm. 2018;40(3):589–98.
428. Bresnahan R, Hounsome J, Jette N, etal. Topiramate add-on therapy for drug-resistant focal
epilepsy. Cochrane Database Syst Rev. 2019;10(10):CD001417.
429. Liu J, Tai YJ, Wang LN.Topiramate for juvenile myoclonic epilepsy. Cochrane Database Syst
Rev. 2021;11(11):CD010008.
430. Knupp KG, Wirrell EC. Treatment strategies for Dravet syndrome. CNS Drugs.
2018;32(4):335–50.
431. Zhang L, Wang J, Wang C. Efcacy and safety of antiseizure medication for LennoxGastaut syndrome: a systematic review and network meta-analysis. Dev Med Child Neurol.
2022;64(3):305–13.
432. Lee SK, Heo K, Kim SE, etal. Effect of number of previous antiseizure medications on
efcacy and tolerability of adjunctive brivaracetam for uncontrolled focal seizures: post hoc
analysis. Adv Ther. 2021;38(7):4082–99.
433. Ji ZY, Huang YQ, He WZ.Sodium valproate combined with topiramate vs. sodium valproate alone for refractory epilepsy: a systematic review and meta-analysis. Front Neurol.
2021;12:794856.
434. Fechner A, Hubert K, Jahnke K, etal. Treatment of refractory and superrefractory status
epilepticus with topiramate: a cohort study of 106 patients and a review of the literature.
Epilepsia. 2019;60(12):2448–58.
435. Welling LC, Rabelo NN, Yoshikawa MH, etal. Efcacy of topiramate as an add-on therapy in
patients with refractory status epilepticus: a short systematic review. Rev Bras Ter Intensiva.
2021;33(3):440–4.
436. Löscher W, Trinka E.The potential of intravenous topiramate for the treatment of status epilepticus. Epilepsy Behav. 2023;138:109032.
307
308
437. Rundfeldt C, Klein P, Boison D, etal. Preclinical pharmacokinetics and tolerability of a novel
meglumine-based parenteral solution of topiramate and topiramate combinations for treatment of status epilepticus. Epilepsia. 2023;64(4):888–99.
438. Vawter-Lee M, Natarajan N, Rang K, etal. Topiramate is safe for refractory neonatal seizures: a multicenter retrospective cohort study of necrotizing enterocolitis risk. Pediatr
Neurol. 2022;129:7–13.
439. Burns TG, Ludwig NN, Tajiri TN, et al. Cognitive and behavioral outcomes among
seizure- controlled children with partial epilepsy on antiepileptic drug monotherapy. Appl
Neuropsychol Child. 2018;7(1):52–60.
440. Knight R, Wittkowski A, Bromley RL.Neurodevelopmental outcomes in children exposed to
newer antiseizure medications: a systematic review. Epilepsia. 2021;62(8):1765–79.
441. Kacirova I, Grundmann M, Brozmanova H, etal. Monitoring topiramate concentrations at
delivery and during lactation. Biomed Pharmacother. 2021;138:111446.
442. Knight R, Craig J, Irwin B, etal. Adaptive behaviour in children exposed to topiramate in the
womb: an observational cohort study. Seizure. 2023;105:56–64.
443. Choi J, Yoon D, Park M, et al. Topiramate-related adverse events: pattern and signals in the Korea Adverse Event Reporting System, 2010-2017. Medicine (Baltimore).
2020;99(42):e22669.
444. Koristkova B, Grundmann M, Brozmanova H, etal. Was it necessary to change the therapeutic range of topiramate? Br J Clin Pharmacol. 2022;88(2):613–8.
445. Khan S, Ashraf A, Javaid H, etal. Topiramate-induced acute transient myopia and angle narrowing. J Coll Physicians Surg Pak. 2021;30(6):728–31.
446. Tyagi M, Behera S, Senthil S, etal. Topiramate induced bilateral hypopyon uveitis and
choroidal detachment: a report of two cases and review of literature. BMC Ophthalmol.
2021;21(1):287.
447. Pinto-Gouveia C, Bernardes L, Renca S.Topiramate-associated acute bilateral angle-closure
glaucoma. J Clin Psychopharmacol. 2022;42(3):320–1.
448. Pelzman DL, Kazi E, Jackman SV, etal. Urinary metabolic disturbances during topiramate
use and their reversibility following drug cessation. Urology. 2022;165:139–43.
449. Shishmanova-Doseva M, Peychev L, Yoanidu L, etal. Anticonvulsant effects of topiramate
and lacosamide on pilocarpine-induced status epilepticus in rats: a role of reactive oxygen
species and inammation. Int J Mol Sci. 2021;22(5):2264.
450. Lotfy DM, Safar MM, Hassan SHM, etal. Modulation of PTZ-induced convulsions in rats
using topiramate alone or combined with low dose gamma irradiation: involving AKT/mTOR pathway. Toxicol Mech Methods. 2022;32(1):18–26.
451. Ra SK, Goering JP, Olm-Shipman AJ, etal. Anti-epileptic drug topiramate upregulates
TGFβ1 and SOX9 expression in primary embryonic palatal mesenchyme cells: implications
for teratogenicity. PLoS One. 2021;16(2):e0246989.
452. Soleimani Meigoni Z, Jabari F, Motaghinejad M, etal. Protective effects of forced exercise
against topiramate-induced cognition impairment and enhancement of its antiepileptic activity: molecular and behavioral evidences. Int J Neurosci. 2022;132(12):1198–209.
453. Borges LI, Forcato S, do Nascimento Olanda LC, etal. Treatment with topiramate in rats
during childhood causes testicular structural impairment at adulthood. J Dev Orig Health
Dis. 2023;14(2):279–85.
454. Paolo P, Matteo F, Rossella L, etal. Koolen-de Vries syndrome: preliminary observations of
topiramate efcacy. Child Neurol Open. 2021;8:2329048x211019183.
455. Chapron SA, Nourredine M, Dondé C, etal. Efcacy and safety of topiramate for reducing
impulsivity: a transdiagnostic systematic review and meta-analysis of a common clinical use.
Fundam Clin Pharmacol. 2022;36(1):4–15.
456. Chandradasa M, Ruwanpriya S, de Silva S, etal. Randomised, placebo-controlled trial on
topiramate add-on therapy for weight reduction and symptomatology in overweight/obese
persons with schizophrenia. Asian J Psychiatr. 2022;68:102963.
W. Jing et al.
2 Antiseizure Medications
457. Panebianco M, Al-Bachari S, Hutton JL, etal. Gabapentin add-on treatment for drug-resistant
focal epilepsy. Cochrane Database Syst Rev. 2021;1(1):CD001415.
458. Ziganshina LE, Abakumova T, Hoyle CHV.Gabapentin monotherapy for epilepsy: a review.
Int J Risk Saf Med. 2023;34(3):243–86.
459. Cao X, Shen Z, Wang X, etal. A meta-analysis of randomized controlled trials comparing the
efcacy and safety of pregabalin and gabapentin in the treatment of postherpetic neuralgia.
Pain Ther. 2023;12(1):1–18.
460. Gammoh O, Al-Smadi A, Shawagfeh MQ, etal. The clinical difference between gabapentin
and pregabalin: data from a pilot comparative trial. Rev Recent Clin Trials. 2021;16(3):279–87.
461. Patel AS, Abrecht CR, Urman RD.Gabapentinoid use in perioperative care and current controversies. Curr Pain Headache Rep. 2022;26(2):139–44.
462. Fowler C, Chu AW, Guo N, et al. Outpatient treatment with gabapentin in women with
severe acute pain after cesarean delivery is ineffective: a randomized, double-blind, placebocontrolled trial. Anesth Analg. 2023;136(6):1122–32.
463. Rudroju N, Bansal D, Talakokkula ST, etal. Comparative efcacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain
Physician. 2013;16(6):E705–14.
464. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults.
Cochrane Database Syst Rev. 2017;6(6):CD007938.
465. Swarm RA, Paice JA, Anghelescu DL, etal. Adult cancer pain, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(8):977–1007.
466. Davanzo R, Dal Bo S, Bua J, etal. Antiepileptic drugs and breastfeeding. Ital J Pediatr.
2013;39:50.
467. Ohman I, Vitols S, Tomson T.Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? Epilepsia.
2005;46(10):1621–4.
468. Fujii H, Goel A, Bernard N, etal. Pregnancy outcomes following gabapentin use: results of a
prospective comparative cohort study. Neurology. 2013;80(17):1565–70.
469. Hayes WJ, Ferdinand A, Neabore S, etal. Patient case report: gabapentin-induced hypoglycemia. J Pharm Pract. 2022;35(2):298–301.
470. Contreras-Mota M, Rosales-Cortés V. [Hepatotoxicity probably associated with gabapentin].
Rev Med Inst Mex Seguro Soc. 2021;59(2):157–62.
471. Largeau B, Bordy R, Pasqualin C, etal. Gabapentinoid-induced peripheral edema and acute
heart failure: a translational study combining pharmacovigilance data and invitro animal
experiments. Biomed Pharmacother. 2022;149:112807.
472. Meaadi J, Obara I, Eldabe S, etal. The safety and efcacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled
trials. Int J Clin Pharm. 2023;45(3):556–65.
473. Evoy KE, Sadrameli S, Contreras J, etal. Abuse and misuse of pregabalin and gabapentin: a
systematic review update. Drugs. 2021;81(1):125–56.
474. Park SH, Hunter K, Berry H, etal. Atrial brillation induced by gabapentin: a case report. J
Med Case Rep. 2023;17(1):236.
475. Perrott SL, Macleod AD. Associations between antiepileptic use and hypogammaglobulinaemia: ndings from a population-based case-control study using data linkage.
Neuroepidemiology. 2023;57(6):355–66.
476. Kaurich T.Drug-induced acute pancreatitis. Proc (Baylor Univ Med Cent). 2008;21(1):77–81.
477. Uchitel OD, Di Guilmi MN, Urbano FJ, etal. Acute modulation of calcium currents and
synaptic transmission by gabapentinoids. Channels (Austin). 2010;4(6):490–6.
478. Chincholkar M.Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations
for clinical practice. Br J Pain. 2020;14(2):104–14.
479. Got T, Vivas L, Fan C, etal. Treatment of hiccups in stroke rehabilitation with gabapentin: a
case series and focused clinical review. Top Stroke Rehabil. 2021;28(6):475–80.
309